Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy

被引：13

作者：

Yokohama, Keisuke ^{[1
]}

Asai, Akira ^{[1
]}

Matsui, Masahiro ^{[1
]}

Okamoto, Norio ^{[1
]}

Yasuoka, Hidetaka ^{[1
]}

Nishikawa, Tomohiro ^{[2
]}

Ohama, Hideko ^{[1
]}

Tsuchimoto, Yusuke ^{[1
]}

Inoue, Yoshihiro ^{[3
]}

Fukunishi, Shinya ^{[1
]}

Uchiyama, Kazuhisa ^{[3
]}

Higuchi, Kazuhide ^{[1
]}

机构：

[1] Osaka Med Coll, Dept Internal Med 2, 2-7 Daigakumachi, Takatsuki, Osaka 5698686, Japan

[2] Hokusetsu Gen Hosp, Internal Med, Takatsuki, Osaka, Japan

[3] Osaka Med Coll, Dept Gen & Gastroenterol Surg, Takatsuki, Osaka, Japan

来源：

SCIENTIFIC REPORTS | 2020年 / 10卷 / 01期

关键词：

ADVERSE EVENTS; ADVANCED MELANOMA; SINGLE-ARM; OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; PD-1; CHEMOTHERAPY; IPILIMUMAB;

D O I：

10.1038/s41598-020-71561-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Immune-related adverse events (irAEs) are induced by immune checkpoint inhibitors (ICI s). Liver is one of the main target organs which irAEs occur and we investigated the influence of liver dysfunction on prognosis of patients after ICIs. From July 2014 to December 2018, 188 patients with diverse cancers who received ICI s (nivolumab or pembrolizumab) were enrolled. Twenty-nine patients experienced liver dysfunction of any grades after ICIs. Progression-free survival (PFS) was significantly shorter in the liver dysfunction-positive group than in the liver dysfunction-negative group, and a similar result was obtained for Overall survival (OS). Multiple logistic regression analysis revealed liver metastasis and alanine aminotransferase before ICI s were associated with a higher incidence of liver dysfunction after ICIs. Regardless of liver metastasis, PFS and OS were significantly shorter in the liver dysfunction-positive group. In conclusion, this study suggests liver dysfunction is associated with poor prognosis in patients after ICI s with diverse cancers.

引用

页数：9

共 50 条

[21] Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy [J].

Cone, Eugene B. ;

Haeuser, Lorine ;

Reese, Stephen W. ;

Marchese, Maya ;

Nguyen, David-Dan ;

Nabi, Junaid ;

Chou, Wesley H. ;

Noldus, Joachim ;

McKay, Rana R. ;

Kilbridge, Kerry Laing ;

Quoc-Dien Trinh .

PLOS ONE, 2022, 17 (11)

[22] Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases [J].

Hao, Yue ;

Xu, Manyi ;

Zeng, Xiaohong ;

Wang, Yina ;

Wang, Wenxian ;

Lin, Gen ;

Li, Bihui ;

Huang, Jianhui ;

Xu, Chunwei ;

Zhang, Yongchang ;

Song, Zhengbo .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16

[23] Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy [J].

Failing, Jarrett J. ;

Dudek, Olivia A. ;

Acevedo, Julian A. Marin ;

Chirila, Razvan M. ;

Dong, Haidong ;

Markovic, Svetomir N. ;

Dronca, Roxana S. .

FUTURE ONCOLOGY, 2019, 15 (22) :2645-2656

[24] Immune checkpoint inhibitor therapy for malignant pleural mesothelioma [J].

Nowak, Anna K. ;

Chin, Wee Loong ;

Keam, Synat ;

Cook, Alistair .

LUNG CANCER, 2021, 162 :162-168

[25] Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis [J].

Rubio-Infante, Nestor ;

Ramirez-Flores, Yoel A. ;

Castillo, Elena C. ;

Lozano, Omar ;

Garcia-Rivas, Gerardo ;

Torre-Amione, Guillermo .

EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (10) :1739-1747

[26] Update on Immune Checkpoint Inhibitor-Associated Uveitis [J].

Kim, Christian ;

Paul, Samantha ;

Echegaray, Jose .

CURRENT OPHTHALMOLOGY REPORTS, 2023, 11 (03) :57-67

[27] Immune Checkpoint Inhibitor-Associated Colits and Hepatitis [J].

Reddy, Haritha G. ;

Schneider, Bryan J. ;

Tai, Andrew W. .

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2018, 9

[28] Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose? [J].

Ramamurthy, Chethan ;

Godwin, James L. ;

Borghaei, Hossein .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)

[29] Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer A Systematic Review [J].

Asdourian, Maria S. ;

Shah, Nishi ;

Jacoby, Ted V. ;

Reynolds, Kerry L. ;

Chen, Steven T. .

JAMA DERMATOLOGY, 2022, 158 (08) :933-941

[30] Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy [J].

Reese, Stephen W. ;

Cone, Eugene ;

Marchese, Maya ;

Garcia, Brenda ;

Chou, Wesley ;

Ayub, Asha ;

Kilbridge, Kerry ;

Weinhouse, Gerald ;

Trinh, Quoc-Dien .

LUNG, 2021, 199 (02) :199-211

← 1 2 3 4 5 →